ReviewJournal of neuro-oncology2009
Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.
Review in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Polypept(o)ide-Based Core-Shell Bottlebrush Polymers: A Versatile Platform for Drug Encapsulation.Macromolecular bioscience · 2025Article
- Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma.International journal of molecular sciences · 2022Article
- A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.Neuro-oncology · 2022Article
- Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments.Frontiers in oncology · 2020Review
- A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-Cancers · 2019Article
- Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.International journal of cancer · 2019Article
- Proinvasive extracellular matrix remodeling in tumor microenvironment in response to radiation.Oncogene · 2018Article
- PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling.Oncotarget · 2016Article
- Src family kinases differentially influence glioma growth and motility.Molecular oncology · 2015Article
- Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.Neuro-oncology · 2015Article
- Dasatinib in recurrent glioblastoma: failure as a teacher.Neuro-oncology · 2015Article
- The role of Src family kinases in growth and migration of glioma stem cells.International journal of oncology · 2014Article
- Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.The Journal of biological chemistry · 2014Article
- Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.BioMed research international · 2014Article
- Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from neuritin.Journal of neuro-oncology · 2013Article
- Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.Molecular therapy. Nucleic acids · 2012Article
- Glutamate and the biology of gliomas.Glia · 2011Review
- Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.Journal of neuro-oncology · 2011Article
- Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.Cancer treatment reviews · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most common and aggressive form of primary brain tumor. The prognosis for patients diagnosed with glioblastoma is poor, with a median survival of 12-14 months and a 5-year survival rate of <5%. The upfront standard treatment for patients with newly diagnosed glioblastoma, consisting of surgery followed by chemotherapy combined with radiotherapy, provides only short-term survival benefits. Recurrent glioblastoma is an extremely challenging therapeutic setting because of the aggressive and resistant nature of the tumor. A set of key molecular targets in oncology is the Src family of non-receptor protein kinases. Dysregulated signaling via the Src kinases has been shown to underlie glioma-related proliferation, angiogenesis, migration, and survival. Here we review the biologic role of Src in malignant glioma and discuss key preclinical studies demonstrating the potential utility of inhibiting Src in glioma. Proof of clinical benefit is forthcoming from the first clinical studies involving the newest generation of small molecule Src inhibitors currently in clinical trials for recurrent glioblastoma. Blocking Src alone will likely not translate into a significant clinical benefit; thus, strategies for combining Src inhibitors with potential synergistic therapeutic modalities will be discussed. This review will focus on dasatinib, the most advanced Src inhibitor being tested in glioblastoma, which is currently in phase I/II trials in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.